.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Farmers Insurance
Deloitte
Argus Health
McKinsey
US Army
Dow
Covington
Fuji
Daiichi Sankyo

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Subscribe

« Back to Dashboard

Details for Patent: ➤ Subscribe

Title: Systemic anti-inflammatory treatment
Abstract:A method of arthritis and other inflammatory diseases in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal to be treated a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier is disclosed.
Inventor(s): Katz; David H. (La Jolla, CA)
Assignee: Lidak Pharmaceuticals (La Jolla, CA)
Filing Date:Jul 29, 1991
Application Number:07/737,492
Claims:1. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

2. The method of claim 1 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

3. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by intramuscular injection a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

4. The method of claim 3 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

5. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by trans-mucus membranal penetration a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

6. The method of claim 5 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

7. A method of treating inflammatory disease in humans or other mammals, comprising introducing into the human or other mammal in need of such treatment by transdermal penetration a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

8. The method of claim 7 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

9. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

10. The method of claim 9 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

11. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by intramuscular injection a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

12. The method of claim 11 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

13. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by trans-mucus membrane penetration a physiologically effective amount of a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

14. The method of claim 13 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.

15. A method of treating arthritis in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal in need of such treatment by transdermal penetration a physiologically effective amount of a composition consisting of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier.

16. The method of claim 15 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier comprising propylene oxide and ethylene oxide block co-polymer non-ionic detergent.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Novartis
US Department of Justice
US Army
AstraZeneca
Fish and Richardson
Baxter
Federal Trade Commission
Cantor Fitzgerald
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot